Relievant Medsystems, Inc.
7
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
42.9%
3 terminated/withdrawn out of 7 trials
57.1%
-29.4% vs industry average
0%
0 trials in Phase 3/4
100%
4 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
INTRACEPT: Prospective, Randomized, Multi-center Study Intraosseous Basivertebral Nerve Ablation for Treatment of CLBP
Role: lead
The Intracept Global Registry ( TIGR ) - Pilot Study
Role: lead
Five-Plus Year Follow-Up of SMART Randomized Controlled Trial
Role: lead
Study of Basivertebral Nerve Ablation Treatment of Chronic Low Back Pain
Role: lead
Intraosseous Basivertebral Nerve Ablation for the Treatment of Chronic Low Back Pain
Role: lead
Intraosseous Basivertebral Nerve Ablation for Treatment of Chronic Low Back Pain
Role: lead
SMART Clinical Study: Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain
Role: lead
All 7 trials loaded